ALDH1A3 and prostate cancer: In the present study, we aimed to investigate the cytotoxicity of DEAB and the recently discovered ALDH-affinic compounds [21] on several ALDH1A3-expressing breast and prostate cancer cell lines as single agents, and in combination with DOX to evaluate the possibility of enhancing sensitization to DOX treatment.